|会社名||BioCryst Pharmaceuticals Inc （バイオクリスト・ファ―マシュ―ティカルズ）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 バイオクリスト・ファーマシューティカルズ（BioCryst Pharmaceuticals Inc.）はバイオテクノロジー企業である。病気の病因に関与する酵素をブロックする小分子薬の設計、最適化と開発を行う。同社は希少疾患の治療に集中する。同社はX線結晶学、分子構造のコンピュータモデリングと化学技術を利用して細胞生物学を制御する酵素の活性部位特性と三次元的な分子構造の解明に集中する。同社の薬剤候補はRAPIVAB、RAPIACTA、ALPIVAB、PERAMIFLU、Avoralstat、BCX7353、他の第二世代遺伝性血管浮腫（HAE）化合物、GalidesivirとForodesineなどを含む。同社の製品RAPIVABはペラミビルを含む。ALPIVABは静脈内ノイラミニダーゼ阻害剤である。Galidesivirは出血熱ウイルスの治療に向けの広域抗ウイルス（BSAV）研究プログラムである。Forodesineはがん治療薬としてMundipharmaによる開発されたプリンヌクレオシドホスホリラーゼ（PNP）阻害剤である。 バイオクリスト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。疾患の発症を引き起こす酵素を阻害する薬剤の開発に従事。インフルエンザ患者の治療薬ペラミビル、痛風治療薬ウロデシン、血液学的悪性腫瘍の治療薬フォロデシン、遺伝性血管性浮腫（HAE）の治療薬BCX4161などの開発を行う。またエボラウィルスの治療用抗ウィルスの研究を手掛ける。 BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.|
|本社所在地||4505 Emperor Blvd. Suite 200 Durham NC 27703 USA|
|代表者氏名||Robert A. Ingram ロバートA.イングラム|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 BioCryst Pharmaceuticals Inc. revenues increased 31% to $16.5M. Net loss increased 42% to $44.2M. Revenues reflect Collaborative and other research and dev increase from $5.7M to $12.7M. Higher net loss reflects General_Administrative increase from $5.9M to $17.1M (expense) Research and development increase of 21% to $39.5M (expense).|
BioCryst to Present at Upcoming Investor Conferences 2022/03/03 12:00:00 GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET. The event will be held virtually.
BioCryst Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/02/25 14:22:49 Seeking Alpha
BioCryst''s Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates 2022/02/24 17:17:13 Benzinga
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX ) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE). The results showed sustained reductions in attack rates and improved quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to … Full story available on Benzinga.com
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat) 2022/02/24 12:00:00 Benzinga
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO. The data are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022. "The long-term data from APeX-2 show that HAE patients in our clinical program had an experience consistent with what we are seeing commercially in the real world; that ORLADEYO provides noteworthy, sustained, consistent reductions in HAE attack rates that persist and maintain over time, resulting in meaningful quality of life improvements," said Dr.
Why BioCryst Pharmaceuticals Stock Slid Today 2022/02/23 23:30:43 The Motley Fool
The biotech''s immediate future doesn''t look profitable.
Inv Corp Small Cap Value Buys Zuora Inc, Home BancShares Inc, Tegna Inc, Sells Zurn Water ... 2021/12/08 23:38:02 GuruFocus
Related Stocks: TGNA , BDC , EQT , COHU , ICFI , SUPN , ZUO , HOMB , BCRX , ZWS , CNXC , SYNA , ISBC , ORBC , CLDR ,
Lets Jump Into The BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Forecast 2021/12/08 14:30:00 Marketing Sentinel
In the last trading session, 3.1 million BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares changed hands as the companys beta touched 2.47. With the companys per share price at $12.21 changed hands at $1.03 or 9.21% during last session, the market valuation stood at $2.28B. BCRXs last price was a discount, traded about -51.35% off its 52-week Lets Jump Into The BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Forecast Read More »
Mutual of America VIP Small-Cap Value Portfolio Buys Zuora Inc, Home BancShares Inc, BioCryst ... 2021/12/07 21:38:04 GuruFocus
Related Stocks: BDC , COHU , ICFI , ARNA , ZUO , HOMB , BCRX , ZWS , CNXC , ISBC , SYNA , ORBC , CLDR ,
North Star Investment Management Corp. Has $6.36 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 2021/12/05 14:04:42 Transcript Daily
North Star Investment Management Corp. lifted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1.4% during the third quarter, Holdings Channel.com reports. The firm owned 442,900 shares of the biotechnology companys stock after acquiring an additional 6,210 shares during the quarter. North Star Investment Management Corp.s holdings in BioCryst Pharmaceuticals were worth $6,364,000 
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 7% 2021/12/02 18:40:43 Transcript Daily
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)s share price rose 7% on Thursday . The stock traded as high as $12.07 and last traded at $12.06. Approximately 51,577 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 4,236,215 shares. The stock had previously closed at $11.27. Several research analysts have recently 
Traders cant mares this Stock: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Outlook Therapeutics, Inc. (NASDAQ:OTLK) 2021/08/01 21:18:15 Stock Equity
BioCryst Pharmaceuticals, Inc. (BCRX) with the stream of -3.82% also noticed, India Outlook Therapeutics, Inc. (OTLK) encountered a rapid change of -6.22% in the last hour of trading session. BioCryst The post Traders cant mares this Stock: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Outlook Therapeutics, Inc. (NASDAQ:OTLK) appeared first on Stocks Equity .
BioCryst Appoints Vincent Milano to Board of Directors 2021/07/28 11:00:00 Intrado Digital Media
RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.
Global Hereditary Angioedema Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pharming Group NV, iBio Inc., Takeda, CSL Limited, Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. 2021/07/23 21:03:54 Jumbo News
The report on Global Hereditary Angioedema Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition 
BioCryst to Report Second Quarter 2021 Financial Results on August 5 2021/07/22 11:00:00 Intrado Digital Media
RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Thursday, August 5, 2021.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 バイオクリスト・ファ―マシュ―ティカルズ BCRX BioCryst Pharmaceuticals Inc.）